JP2009537502A - 癌および他の疾患の治療のための３６−デス（３−メトキシ−４−ヒドロキシシクロヘキシル）−３６−（３−ヒドロキシシクロヘプチル）ラパマイシン誘導体 - Google Patents

癌および他の疾患の治療のための３６−デス（３−メトキシ−４−ヒドロキシシクロヘキシル）−３６−（３−ヒドロキシシクロヘプチル）ラパマイシン誘導体 Download PDF

Info

Publication number
JP2009537502A
JP2009537502A JP2009510551A JP2009510551A JP2009537502A JP 2009537502 A JP2009537502 A JP 2009537502A JP 2009510551 A JP2009510551 A JP 2009510551A JP 2009510551 A JP2009510551 A JP 2009510551A JP 2009537502 A JP2009537502 A JP 2009537502A
Authority
JP
Japan
Prior art keywords
compound according
compound
acid
treatment
represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009510551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537502A5 (https=
Inventor
バリー ウィルキンソン，
ミン−チーアン チャン，
ローズ マリー シェリダン，
クリストフ ベックマン，
Original Assignee
バイオティカ テクノロジー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオティカ テクノロジー リミテッド filed Critical バイオティカ テクノロジー リミテッド
Publication of JP2009537502A publication Critical patent/JP2009537502A/ja
Publication of JP2009537502A5 publication Critical patent/JP2009537502A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009510551A 2006-05-19 2007-05-18 癌および他の疾患の治療のための３６−デス（３−メトキシ−４−ヒドロキシシクロヘキシル）−３６−（３−ヒドロキシシクロヘプチル）ラパマイシン誘導体 Pending JP2009537502A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0609962.6A GB0609962D0 (en) 2006-05-19 2006-05-19 Novel compounds
PCT/GB2007/001856 WO2007135397A1 (en) 2006-05-19 2007-05-18 36 -des (3 -methoxy-4 -hydroxycyclohexyl) 36 - (3 -hydroxycycloheptyl) derivatives of rapamycin for the treatment of cancer and other disorders

Publications (2)

Publication Number Publication Date
JP2009537502A true JP2009537502A (ja) 2009-10-29
JP2009537502A5 JP2009537502A5 (https=) 2011-05-12

Family

ID=36660469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009510551A Pending JP2009537502A (ja) 2006-05-19 2007-05-18 癌および他の疾患の治療のための３６−デス（３−メトキシ−４−ヒドロキシシクロヘキシル）−３６−（３−ヒドロキシシクロヘプチル）ラパマイシン誘導体

Country Status (10)

Country Link
US (1) US20090209572A1 (https=)
EP (1) EP2027130A1 (https=)
JP (1) JP2009537502A (https=)
CN (1) CN101443333A (https=)
AU (1) AU2007253118A1 (https=)
BR (1) BRPI0711945A2 (https=)
CA (1) CA2651405A1 (https=)
GB (1) GB0609962D0 (https=)
MX (1) MX2008014746A (https=)
WO (1) WO2007135397A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2601201B1 (en) 2010-08-04 2014-09-24 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
EP2670756B1 (en) * 2011-02-04 2017-06-21 Synthon BV Process for making everolimus
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
CN102786534A (zh) * 2012-05-25 2012-11-21 上海现代制药股份有限公司 一种依维莫司的制备方法
CN113244399A (zh) 2015-01-26 2021-08-13 耶鲁大学 利用酪氨酸激酶抑制剂的组合物和方法
EP3109250A1 (en) 2015-06-23 2016-12-28 Synbias Pharma AG Method for the synthesis of rapamycin derivatives
CN106916835B (zh) * 2015-12-24 2022-08-12 武汉合生科技有限公司 化合物的生物合成基因簇及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
WO1992021341A1 (en) * 1991-05-31 1992-12-10 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5912253A (en) * 1993-12-17 1999-06-15 Novartis Ag Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
CA2492153C (en) * 2002-07-16 2012-05-08 Biotica Technology Limited Production of polyketide fkbp-ligand analogues

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012062910; ＣｈｅｍＢｉｏＣｈｅｍ Ｖｏｌ．５, 2004, Ｐ．５３５-５３８ *
JPN6012062913; Ａｎｇｅｗａｎｄｔｅ　Ｃｈｅｍｉｅ，　Ｉｎｔｅｒｎａｔｉｏｎａｌ　Ｅｄｉｔｉｏｎ Ｖｏｌ．４４, 2005, Ｐ．４７５７-４７６０ *

Also Published As

Publication number Publication date
US20090209572A1 (en) 2009-08-20
BRPI0711945A2 (pt) 2011-12-13
EP2027130A1 (en) 2009-02-25
CA2651405A1 (en) 2007-11-29
WO2007135397A1 (en) 2007-11-29
CN101443333A (zh) 2009-05-27
MX2008014746A (es) 2009-02-19
GB0609962D0 (en) 2006-06-28
AU2007253118A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
JP5422788B2 (ja) ラパマイシンの３９−デスメトキシ誘導体
JP3725901B2 (ja) ラパマイシンヒドロキシエステル、それらの製造方法、および、それらを含有する医薬組成物
MXPA96004694A (en) Hydroxysteres of rapamycin, process for supreparation and pharmaceutical compositions that loscontie
NZ242778A (en) Amide esters of rapamycin and pharmaceutical compositions thereof
JP2009537502A (ja) 癌および他の疾患の治療のための３６−デス（３−メトキシ−４−ヒドロキシシクロヘキシル）−３６−（３−ヒドロキシシクロヘプチル）ラパマイシン誘導体
WO2002026746A2 (en) 1-oxorapamycins
JP2009537504A (ja) 癌および他の疾患の治療のための３９−デスメトキシ−３９−メチルラパマイシン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130425